CA2537360A1 - Methods and compositions for treating herpes infections - Google Patents

Methods and compositions for treating herpes infections Download PDF

Info

Publication number
CA2537360A1
CA2537360A1 CA002537360A CA2537360A CA2537360A1 CA 2537360 A1 CA2537360 A1 CA 2537360A1 CA 002537360 A CA002537360 A CA 002537360A CA 2537360 A CA2537360 A CA 2537360A CA 2537360 A1 CA2537360 A1 CA 2537360A1
Authority
CA
Canada
Prior art keywords
herpes
composition
disease
iga
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537360A
Other languages
English (en)
French (fr)
Inventor
Ulrich Betz
Klaus-Peter Radtke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2537360A1 publication Critical patent/CA2537360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002537360A 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections Abandoned CA2537360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/656,781 2003-09-05
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
PCT/US2004/028559 WO2005025617A2 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Publications (1)

Publication Number Publication Date
CA2537360A1 true CA2537360A1 (en) 2005-03-24

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537360A Abandoned CA2537360A1 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Country Status (13)

Country Link
US (3) US6984492B2 (enExample)
EP (1) EP1663309A2 (enExample)
JP (1) JP2007504268A (enExample)
KR (1) KR20060107509A (enExample)
CN (1) CN1845756A (enExample)
AU (1) AU2004272001A1 (enExample)
BR (1) BRPI0414139A (enExample)
CA (1) CA2537360A1 (enExample)
IL (1) IL173805A0 (enExample)
NO (1) NO20061184L (enExample)
NZ (1) NZ546303A (enExample)
WO (2) WO2005023303A1 (enExample)
ZA (1) ZA200602738B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2248825T3 (pl) 2009-05-04 2013-04-30 Ribovax Biotechnologies Sa Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
WO2014070786A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
RU2703903C2 (ru) * 2014-06-26 2019-10-22 Хайдельберг Иммунотерапьютикс Гмбх Местное применение антитела к hsv
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020097528A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
US5681565A (en) 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
WO1998046240A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
JP2007504268A (ja) 2007-03-01
BRPI0414139A (pt) 2006-10-31
CN1845756A (zh) 2006-10-11
US6984492B2 (en) 2006-01-10
KR20060107509A (ko) 2006-10-13
US20090232798A1 (en) 2009-09-17
US20060198848A1 (en) 2006-09-07
WO2005025617A2 (en) 2005-03-24
WO2005025617A3 (en) 2005-05-26
IL173805A0 (en) 2006-07-05
NZ546303A (en) 2009-03-31
EP1663309A2 (en) 2006-06-07
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
ZA200602738B (en) 2008-06-25
NO20061184L (no) 2006-06-01
WO2005023303A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
US20090232798A1 (en) Methods and compositions for treating herpes infections
AU2016293004B2 (en) Stuffy nose deblocking composition having antiviral activity
US20120082658A1 (en) Methods for the Treatment of Allergic Diseases
US4462986A (en) Synergistic anti-herpes compositions
CN111249288B (zh) 甘露葡萄糖醛酸寡糖及其衍生物在制备治疗和/或预防hcmv药物中的应用
MXPA06002585A (en) Methods and compositions for treating herpes infections
JP4580479B2 (ja) 抗ｈｉｖ感染症剤
Higgins et al. Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers
Kemertelidze et al. Therapeutic effect of phenolic compounds isolated from Rhododendron ungernii leaves
EP0641569A1 (en) Antipruritic
CA1302887C (en) Combination of acyclovir or a derivative thereof and bacitracin
KR20010108040A (ko) 항-ｈｉｖ 감염증제 및 ｈｉｖ 감염증의 치료 방법
JP3266254B2 (ja) ヘルペス関連疾患の治療方法および組成物
RU2847403C1 (ru) Способ лечения иммунодефицита внутривенным введением аминодигидрофталазиндиона натрия
US4230725A (en) Antiviral agent
US6495678B1 (en) Immunosuppressant containing glucopyranose derivative as active ingredient
Nicholson Antiviral Therapy: Respiratory Infections, Genital Herpes, and Herpetic Keratitis
Vilas et al. Effect of a Uridine 5′-Diphosphate Glucose Analogue, on Herpes simplex keratitis in Rabbits and Vaginal Infection, in Guinea Pigs
JPH10330257A (ja) 眼局所用サイトカイン産生抑制剤
Martin et al. Antiviral activity of a D‐glucosamine derivative against herpetic ulcers (HSV type 2) in rabbit cornea
JPH0977684A (ja) 自己免疫抑制性ｔ細胞の活性化剤
CA2008911C (en) Process for preparing ethyl 6-bromo-5-hydroxy-4- dimethylaminomethyl-1-methyl-2-phenylthiomethylindole-3- carboxylate hydrochloride monohydrate and a pharmaceutical preparation containing the same having the antiviral, interferon-inducing and immunomodulatory effects
WO2021210851A1 (ko) 태반추출물을 포함하는 항바이러스 조성물
Chowchuvech et al. The influence of polyinosinic-polycytidylic acid complex on vaccinia keratitis in rabbits
JPH09328426A (ja) トリテルペン誘導体を有効成分とするヘルペスウイルスに起因するヘルペスウイルス感染症治療剤および感染症再発予防剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued